Endocrinology, Vol 135, 76-82, Copyright © 1994 by Endocrine Society

ARTICLES

Insulin-like growth factor-II enhancement of human fibroblast growth via a nonreceptor-mediated mechanism

CA Conover, JT Clarkson and LK Bale
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905.

Deciphering the complex interactions of the various components of the insulin-like growth factor (IGF) system [IGF-I and -II peptides, type I and II IGF receptors, and IGF-binding proteins (IGFBPs)] is important for our understanding of cell growth regulation. We report here that IGF-II can enhance IGF-I-stimulated cell proliferation independent of direct IGF-II interaction with type I or II IGF receptors. Human fibroblasts cultured in serum-free medium for 40 h were relatively resistant to the mitogenic effects of added IGF-I. However, preexposure of the cultures to low concentrations of IGF-II enhanced IGF-I action several-fold. IGF-II by itself had no stimulatory effect and did not influence [Gln3,Ala4,Tyr15,Leu16]IGF-I or insulin-stimulated DNA synthesis. IGF-II did not directly interact with type I IGF receptors, as [Leu27]IGF-II, an IGF-II analog that does not bind type I IGF receptors, could mimic IGF-II's potentiating effect. Type II IGF receptors also were not involved because 1) [Gln6,Ala7,Tyr18,Leu19,Leu27]IGF-II, an analog with normal receptor binding, had no effect; and 2) beta-galactosidase, a competitive inhibitor of IGF-II receptor binding, did not influence IGF-II potentiation of IGF-I action. Enhanced cell responsiveness to IGF-I appears to be due to IGF-II-induced changes in pericellular IGFBP-3 and IGFBP-4. These data support the hypothesis that IGF-II can potentiate the action of IGF-I by disrupting the IGFBP barrier at the cell surface, thereby increasing IGF-I availability for type I IGF receptor interaction.

This article has been cited by other articles:

				J M Fleming, B J Leibowitz, D E Kerr, and W S Cohick IGF-I differentially regulates IGF-binding protein expression in primary mammary fibroblasts and epithelial cells J. Endocrinol., July 1, 2005; 186(1): 165 - 178. [Abstract] [Full Text] [PDF]

				Z. T. Resch, B.-K. Chen, L. K. Bale, C. Oxvig, M. T. Overgaard, and C. A. Conover Pregnancy-Associated Plasma Protein A Gene Expression as a Target of Inflammatory Cytokines Endocrinology, March 1, 2004; 145(3): 1124 - 1129. [Abstract] [Full Text] [PDF]

				B.-K. Chen, M. T. Overgaard, L. K. Bale, Z. T. Resch, M. Christiansen, C. Oxvig, and C. A. Conover Molecular Regulation of the IGF-Binding Protein-4 Protease System in Human Fibroblasts: Identification of a Novel Inducible Inhibitor Endocrinology, April 1, 2002; 143(4): 1199 - 1205. [Abstract] [Full Text] [PDF]

				A. Bayes-Genis, R. S. Schwartz, D. A. Lewis, M. T. Overgaard, M. Christiansen, C. Oxvig, K. Ashai, D. R. Holmes Jr, and C. A. Conover Insulin-Like Growth Factor Binding Protein-4 Protease Produced by Smooth Muscle Cells Increases in the Coronary Artery After Angioplasty Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 335 - 341. [Abstract] [Full Text] [PDF]

				N. Miyakoshi, C. Richman, X. Qin, D. J. Baylink, and S. Mohan Effects of Recombinant Insulin-Like Growth Factor-Binding Protein-4 on Bone Formation Parameters in Mice Endocrinology, December 1, 1999; 140(12): 5719 - 5728. [Abstract] [Full Text]

				C. A. Conover, S. K. Durham, Jür. Zapf, F. R. Masiarz, and M. C. Kiefer Cleavage Analysis of Insulin-like Growth Factor (IGF)-dependent IGF-binding Protein-4 Proteolysis and Expression of Protease-resistant IGF-binding Protein-4 Mutants J. Biol. Chem., March 3, 1995; 270(9): 4395 - 4400. [Abstract] [Full Text] [PDF]